PPTA Honored in House of Representatives
SPEECH OF HON. KEVIN BRADY OF TEXAS IN THE HOUSE OF REPRESENTATIVES
Library of Congress [Page: E979]
Mr. Speaker, I rise today to honor the Plasma Protein Therapeutics Association (PPTA) as that organization celebrates its 20th anniversary.
Since PPTA's founding in 1992, the organization has been at the forefront of promoting innovation and patient access to safe and effective therapies used to treat rare and chronic conditions. PPTA is a globally active trade association, representing six plasma protein therapy manufacturers in the United States, and 16 plasma collection companies that operate nearly 400 plasma collection centers across the country.
PPTA is distinguished in the pharmaceutical and biologics industries for the Association's dedication to the continual innovation of therapies for rare disease patients. Today, plasma protein therapies are used to treat a range of rare diseases including primary immune deficiency diseases; neurological disorders such as chronic inflammatory demyelinating polyneuropathy; hemophilia, von Willebrand disease and other bleeding disorders; and alpha 1 antitrypsin deficiency, as well as specialty immune globulin therapies that treat a range of conditions. Recognizing the unique concerns of the patients living with these rare diseases, PPTA continues to act as a diligent advocate for the protection of therapeutic innovation and patient access to plasma protein therapies. One example of that commitment is the Association's strong support of my bill, the Medicare IVIG Access Act, H.R. 1845, which will make whole the home infusion benefit for patients with primary immune deficiencies. In addition to my work on this legislation, my interest, support, and commitment extend to all of the rare disease patients treated with life-saving plasma protein therapies, and I'm proud to work on issues so vital to the health of these fragile groups of patients.
In addition to the Association's outstanding advocacy, PPTA has also led the industry in quality and safety assurance. In 2000, PPTA and its members implemented the Quality Standards of Excellence, Assurance and Leadership (QSEAL) as voluntary standards that complement FDA regulatory requirements for manufacturing plasma protein therapeutics. QSEAL certification provides a pathway for industry participants to provide independent certification of adherence to the QSEAL standards. The QSEAL program works in concert with the International Quality Plasma Program (IQPP), instituted more than 20 years ago to help ensure the safety of plasma used to produce lifesaving therapies and plasma donors.
A global organization headquartered in the United States, with an office in Belgium, and that serves the needs of chronic, rare disease patients around the world, PPTA and its members should be commended for their ongoing commitment to supporting patient access to innovative, safe and effective treatments.
- Created on .